Phase 4
Completed N=100
Glucagon Use in Colonoscopies
Source: ClinicalTrials.gov NCT02078726 ↗Enrolled (actual)
100
Serious AEs
0.0%
Results posted
Apr 2021
Primary outcomePrimary: Adenoma Detection Rate (ADR) During Colonoscopy Procedure — 43.75; 33.33 percentage of participants
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The investigators believe that glucagon therapy will have a positive impact on key parameters of colonoscopy such as cecal intubation time, withdrawal time, total procedure time, adenoma detection rate, endoscopist's assessment of the difficulty of the procedure, patient comfort, and patient's willingness to undergo a repeat colonoscopy.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Adenoma Detection Rate (ADR) During Colonoscopy Procedure |
43.75; 33.33 | — |
Eligibility Criteria
Inclusion Criteria
- Any subject who has already been already cleared for and scheduled to undergo colonoscopy at SFGH endoscopy center.
Exclusion Criteria
- Refusal to give informed consent.
- Age 70.
- Prior intra-abdominal surgery
- Diabetes
- Pheochromocytoma
- Insulinoma
- Liver disease (Child-Pugh Score >6)
- Pregnancy
Data sourced from ClinicalTrials.gov (NCT02078726). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.